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ABSTRACT
Background. Treatment decisions and prognosis assess-
ment for liposarcoma is based on a classiﬁcation that
depends on morphological and genetic features. Revisions
by experienced referral pathologists are often advocated.
Methods. The process of histopathological classiﬁcation
in referring hospitals and subsequently in a referral center
in relation to molecular biological information is evaluated.
A total of 331 consecutive liposarcoma patients were
evaluated for the added value of histological review at time
of referral. Subsequently, cases were reclassiﬁed with
implementation of present-day molecular information. For
all patients, complete data on staging, treatment, and fol-
low-up were available.
Results. Upon histological revision, 15/54 (28%) diagno-
ses were reclassiﬁed in the ﬁrst decade, 14/65 (22%) in the
second, and 14/53 (26%) in the last decade. Molecular
biological analysis enabled well-differentiated liposarcoma
with or without dedifferentiated component to be better
recognized as such and distinguished from myxoid lipo-
sarcoma and pleomorphic liposarcoma. Inclusion of
cytogenetic information resulted in reclassiﬁcation after
revision in 4/18 (22%) cases in the ﬁrst decade, 10/38
(26%) cases in the second decade, and 19/75 (25%) cases
in the last decade.
Conclusions. This study indicates that liposarcomas are
heterogeneous tumors. Expert assessment and implemen-
tation of molecular biological analysis are valuable for
adequate classiﬁcation as a basis for treatment decisions.
Liposarcomas are a rare and heterogeneous group of
malignant neoplasms. Treatment decisions and prognosis
assessment for patients with liposarcomas is based on a
classiﬁcation that depends on morphological and genetic
features of the tumor. According to the World Health
Organization (WHO) classiﬁcation, liposarcomas can be
divided into morphological subtypes that are characterized
by a distinct morphological spectrum and clear molecular
features. The ﬁrst category is well-differentiated liposar-
coma and includes a variety of histological subtypes:
lipoma-like, sclerosing, inﬂammatory, and spindle cell
subtypes. The second category is dedifferentiated liposar-
coma and can be found in up to 10% of well-differentiated
liposarcoma of any type and has a more aggressive course.
The third category consists of myxoid liposarcoma, of
which a proportion of cases progress to round cell lipo-
sarcoma. The last category consists of pleomorphic
liposarcoma.
1 At clinical presentation these tumors range
from small superﬁcial low-grade tumors to large inﬁltrating
poorly differentiated retroperitoneal tumors.
2
Differentiation between lipomas and liposarcomas and
the classiﬁcation into subtypes is essential in tailoring
treatment and for prognostic information. In contrast to
lipomas, most liposarcomas should be widely excised to
avoid recurrence. Myxoid/round cell liposarcoma is a
highly radiosensitive tumor.
3–5 Chemotherapy sensitivity
varies considerably between liposarcoma subtypes, with a
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DOI 10.1245/s10434-009-0806-9signiﬁcant higher response rate to ﬁrst-line chemotherapy
in myxoid/round cell liposarcoma as compared with well-/
dedifferentiated liposarcoma (48% versus 11%).
6 More-
over, favorable response to speciﬁc agents such as
trabectedin have been described for myxoid liposarcoma.
7
Furthermore, in contrast to other types of liposarcoma,
myxoid/round cell liposarcomas is speciﬁcally character-
ized by its multifocal extrapulmonary presentation.
Therefore, particular attention to this characteristic extra-
pulmonary metastasizing pattern is advocated in staging
myxoid and round cell liposarcoma.
Over the last few years, several studies focusing on
lipomatous tumors have led to the delineation of new
variants as well as to the introduction of new concepts,
mainly as a result of fruitful interactions between molec-
ular genetics and pathology. As a result, genetic alterations
are now considered as an integral part of the WHO clas-
siﬁcation. Characteristic genetic alteration for well- and
dedifferentiated liposarcoma is the ampliﬁcation of the
12q13-15 region, which amongst other genes, includes
MDM2 and CDK4.
8,9 The class of myxoid/round cell lip-
osarcoma is characterized by a classical t(12;16) (q13;p11)
or t(12;22) (q13;q12) translocation, with a FUS–CHOP or
EWSR1–CHOP gene fusion respectively.
10–14 These alter-
ations are mutually exclusive and distinctive for their
disease class.
For the classiﬁcation of lipomatous tumors, revision of
slides by an experienced referral pathologist or a reference
panel is frequently performed. Analysis of molecular bio-
logical changes in lipomatous tumors has provided new
expert information in liposarcoma management. Here, we
compared pathologic liposarcoma reports and evaluated
diagnostic discrepancies of histopathological liposarcoma
classiﬁcation in referring hospitals and our referral center
in relation to additional available molecular biological
classiﬁcations.
METHODS
Patient Cohort
All liposarcoma patients treated at The Netherlands
Cancer Institute between 1977 and 2006 were evaluated
(n = 331). Original diagnosis by a referring pathologist
and diagnosis by a pathologist at The Netherlands Cancer
Institute at revision that were available were recorded
(n = 246). In 85 cases the patient was initially admitted to
our tertiary hospital.
At referral, immunohistochemical analysis was used for
exclusion of other sarcoma classes of other histogenetic
backgrounds. Histological evaluation by a referral pathol-
ogist was performed without knowledge of molecular
biological analysis. The additional value of molecular
biological analysis was then evaluated.
Molecular Biological Analysis of Region 12q13-15 by
MDM2 and CDK4 Analysis with Multiplex Ligation-
Dependent Probe Ampliﬁcation
Multiplex ligation-dependant probe ampliﬁcation tech-
nique is a high-throughput polymerase chain reaction
(PCR)-based method to determine the relative copy num-
ber of various DNA sequences in small samples of human
DNA. It is based on the annealing of a mixture of hemip-
robes on their cognate DNA sequences. One of the
hemiprobes contains stuffer DNA of variable length (19–
370 bp), which allows multiplex detection using capillary
sequencer.
The Multiplex Ligation-Dependent Probe Ampliﬁcation
Kit P172 test (MRC-Holland, Amsterdam, The Nether-
lands) was used.
15 Target DNA (200 ng) in 5 ll1 0m M
Tris (pH8)/0.1 mM ethylenediamine tetraacetic acid
(EDTA) was denatured for 5 min at 98C, after which 3 ll
probe mix was added. The mixture was heated at 95C for
1 min and incubated at 60C overnight (16 h). Ligation
was performed with the temperature-stable Ligase-65
enzyme (MRC-Holland, Amsterdam, The Netherlands) for
15 min at 54C. Then, the ligase was inactivated by incu-
bation for 5 min at 98C. Ten microliters of this ligation
mix was premixed with 30 ll PCR buffer and put in a PCR
machine at 60C. Subsequently, 10 ll mix was added,
containing deoxynucleoside triphosphate, Taq polymerase,
and one unlabeled and one carboxyﬂuorescein-labeled PCR
primer, being complementary to the universal primer
sequences. PCR was carried out for 35 cycles (30 s at
95C, 30 s at 60C, and 60 s at 72C). The fragments were
analyzed on a ABI model 310 or 3700 capillary sequencer
(Applied Biosystems) using Genescan-ROX 500 size
standards (Applied Biosystems). Fragment analysis was
performed using Genescan and Genotyper software,
ampliﬁcation or deletions were calculated and evaluated
while compared with 15 samples of DNA from normal
tissue. After normalization, each probe set was scored as:
0.01–1.00, deleted; 1.01–2.99, normal copy number; 3.00–
3.99, copy number gain; C4.00, ampliﬁcation.
Detection of FUS–CHOP and EWSR1–CHOP Gene
Fusion
RNA was extracted from representative sections of the
formalin-ﬁxed parafﬁn-embedded specimens according to
the manufacturer’s method using high-purity RNA paraf-
ﬁn kit (Roche, Basel, Switzerland). Microdissection to
optimize tumor cell content was performed if necessary.
RNA concentration was measured using a nanodrop
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ﬁcation was done using one-step RT-PCR. Due to the
limiting quality of RNA from formalin-ﬁxed parafﬁn-
embedded material, different breakpoints were detected,
using a combination of FUS–CHOP- and EWSR1–CHOP-
speciﬁc internal primers, resulting in small PCR products.
2
PCR cycles were operated on a regimen of 30 s of dena-
turation at 95C, 30 s of primer annealing at 68C, and 30 s
extension/synthesis at 72C, for 30 cycles. PCR products
were separated by electrophoresis on 2.5% agarose gels
containing ethidium bromide, visualized by ultraviolet
(UV) light, and photographed. To conﬁrm the type of
fusion gene, PCR products were compared with positive
controls of the different gene fusion combinations as con-
ﬁrmed by sequencing.
Treatment for Primary Liposarcomas
Lipomatous tumor larger than 3 cm were analyzed by
imaging techniques. Biopsy was performed on all lipo-
matous tumors that the images suggested to be malignant.
Sites of potential metastasis were evaluated by computed
tomography (CT). Until 2000, most liposarcomas were
treated with surgery and radiotherapy, irrespective of
subtype or grade. After 2000, tailored treatment was
introduced for subgroups. Surgery was the standard therapy
for liposarcoma; (neo)adjuvant radiotherapy was consid-
ered for all intermediate- and high-grade liposarcomas with
tumor-free margin of less than 10 mm in the absence of an
intact fascial layer and for most recurrent cases not irra-
diated at primary presentation. Preoperative biopsies in
radiological low-grade lipoma-like liposarcomas were
considered redundant, as histologic evaluation of biopsies
in these cases will not differentiate between benign deep-
seated intramuscular lipomas and atypical lipomatous
tumors/well-differentiated liposarcomas, and in all these
patients the surgical procedure would aim for complete
resection with narrow but free margins.
Palliative local treatment or chemotherapy was offered
to patients with inoperable or nearly inoperable disease or
with metastases according to the prevailing guidelines.
6
Patient Follow-Up
In general, patient follow-up consisted of visits at 3-
month intervals during the ﬁrst year after treatment for the
primary tumor, at 6-month intervals during the next
4 years, and at 1-year intervals thereafter. Magnetic reso-
nance imaging of primary tumor site was obtained
3 months after resection. Follow-up visits consisted of
physical examination and chest radiography. Magnetic
resonance imaging or CT was performed on speciﬁc indi-
cations. Patients were discharged from follow-up after
15 years or more without evidence of disease. Overall
survival was deﬁned as time between ﬁrst presentation to
date of last follow-up or death.
Statistical Analysis
Survival of revised liposarcomas patients was visualized
by a Kaplan–Meier method, and an estimation of disease-
speciﬁc survival of the various subclasses was made. The
pairwise log-rank test over the different strata was used to
calculate signiﬁcance among the survival curves. Statistical
analysis was performed using Statistical Package for the
Social Sciences software version 15.0.1 (SPSS, Chicago,
IL). The primary end-point of this analysis was disease-
speciﬁc survival. Ten-year estimates of disease-speciﬁc
survival and the corresponding 95% conﬁdence intervals
are reported.
RESULTS
A total of 331 patients (188 males, 143 females) were
analyzed. Eighty-ﬁve patients were diagnosed in our
institute. Histological evaluation in the remaining 246
patients was initially performed at the referring hospital.
Additional molecular biological analysis was performed in
131 patients, including 80 referred patients. Additionally
34 lipomas were randomly retrieved from the hospital ﬁles
to complete the lipomatous tumor spectrum. Molecular
analyses were also performed on these cases.
Evaluation of Referring Classiﬁcation by Histologic
Revision in a Referral Center
Detailed information on the original and revised histo-
logical diagnoses is listed in Table 1.
Twenty of 23 lipomatous tumors diagnosed by a refer-
ring pathologist as lipoma were reclassiﬁed as well-
differentiated liposarcoma (87%). These patients had all
been referred for local recurrence. The initial diagnosis was
changed to a grade 1 sarcoma in 22/23 (96%) cases and to
grade 2 myxoid liposarcoma in 1/23 (4%) case. Most
tumors were located on the extremities 15/23 (65%), others
being in the head and neck region 4/23 (17%) or the trunk
4/23 (17%). The median frequency of local recurrence
before referral for lipomas was 1 (range 0–5); 16/23 (70%)
recurred at least once after initial treatment. These clinical
ﬁndings underline the correctness of the referral
reclassiﬁcation.
Pathologists in the referring hospital and our tertiary
referral center concurred on the diagnosis of well-differ-
entiated liposarcoma in 18/25 (72%) patients. The others
were revised to dedifferentiated liposarcoma 4/25 (16%) or
688 R. S. A. de Vreeze et al.myxoid liposarcoma 3/25 (12%). The majority of these
cases (12/25, 48%) were situated on the extremities,
whereas 10/25 (40%) had a primary location in the retro-
peritoneum. There was consensus on the diagnosis of
retroperitoneal tumors in 9/10 (90%), and in 7/12 (58%) of
the referred extremity well-differentiated liposarcomas
there was agreement. In this tumor group disagreement was
predominantly found in extremity lesions.
In the group of lipomatous tumors that were classiﬁed as
myxoid/ round cell liposarcoma by a referring pathologist,
there was agreement in 92/99 (93%) patients between
histopathological analysis of referring hospital and revision
classiﬁcation. The reclassiﬁcations (4/7, 57%) were pre-
dominantly retroperitoneal liposarcomas. A similar high
degree of agreement was found for round cell tumors. Only
1/7 (14%) was reclassiﬁed after revision to well-differen-
tiated liposarcoma.
Reclassiﬁcation of pleomorphic liposarcoma occurred in
4/13 (31%). Three of the four were changed to dediffer-
entiated liposarcoma.
Reassessment of Referral Classiﬁcation by Molecular
Biological Information
Detailed information on revised histological diagnoses
and molecular biological analysis is listed in Table 2.
Molecular biological analysis conﬁrmed the histological
reclassiﬁcation at revision to well-differentiated liposar-
coma in all seven referred lipomas that had ampliﬁcation
on region 12q13-15. The randomly selected and reviewed
TABLE 1 Histologic classiﬁcation in referring hospital compared with histologic classiﬁcation in a referral hospital by decades
1977–1986 1987–1996 1997–2006 Changed
diagnosis
Referring
Hospital
Referral
hospital
Referring
Hospital
Referral
hospital
Referring
Hospital
Referral
hospital
Lipoma (8) Lipoma (1) Lipoma (10) Lipoma (5)
WLS (6) WLS (9) WLS (5) 22/23 (96%)
MLS (1) MLS (1)
WLS (6) WLS (3) WLS (10) WLS (9) WLS (9) WLS (6)
DLS (1) DLS (1) DLS (2) 7/25 (28%)
MLS (2) MLS (1)
DLS (0) DLS (1) DLS (1) DLS (4) DLS (3) 1/5 (20%)
PLS (1)
WLS (2) WLS (2) DLS (2)
7/99 (7%) MLS (32) MLS (29) MLS (38) MLS (= 36) MLS (29) MLS (27)
PLS (1)
WLS (1) WLS (1) 2/7 (29%)
RLS (4) RLS (3) RLS (2) RLS (1) RLS (1) RLS (1)
MLS (1) DLS (3) 4/13 (31%)
PLS (4) PLS (3) PLS (4) PLS (4) PLS (5) PLS (2)
WLS (3) WLS (11) WLS (3)
DLS (1) DLS (2) DLS (4) n.a.
MLS (22) MLS (6) MLS (2)
RLS (0) RLS (3) RLS(0)
PLS (8) PLS (3) PLS (3)
(Lipo)sarcoma
N.O.S. (35)
Liposarcoma
N.O.S. (1)
(Lipo)sarcoma
N.O.S. (25)
(Lipo)sarcoma
N.O.S. (14)
(Lipo)sarcoma
N.O.S. (2)
43/172 (25%)
n.a = 74
N = 246
Original diagnosis by a referring pathologist and diagnosis by a pathologist at The Netherlands Cancer Institute at revision that were available
were recorded (n = 246). In 85 cases of liposarcoma the patient was initially admitted to our tertiary hospital
WLS, well-differentiated liposarcoma, DLS dedifferentiated liposarcoma, MLS myxoid liposarcoma, RLS round cell liposarcoma, PLS pleo-
morphic liposarcoma, N.O.S. not otherwise speciﬁed, n.a. not applicable
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34 (3%) of cases.
Molecular analysis of lipomatous tumors that were
reclassiﬁed as well-differentiated liposarcomas showed that
in 47/63 (75%) of cases an ampliﬁcation of region 12q13-15
was found, supporting a diagnosis of well-differentiated
liposarcoma. In the remaining lipomatous tumors that were
considered as well-differentiated liposarcomas 15/63 (23%)
no ampliﬁcation of region 12q13-15 was found (Fig. 1c).
Molecular biological analysis to demonstrate the classic
translocation was performed in 30/92 (33%) lipomatous
tumors revised as myxoid liposarcoma and conﬁrmed the
diagnosis in 18 (60%) of these cases, supporting the clas-
siﬁcation of myxoid liposarcoma. All retroperitoneal
liposarcomas that were histologically classiﬁed as myxoid
liposarcoma at revision (n = 11) were reclassiﬁed as well-
differentiated liposarcoma in view of the absence of the
classic translocation and because of presence of ampli-
ﬁcation of region 12q13-15 on molecular biological
analysis. One extremity sarcoma was revised to myxoid
liposarcoma, but none of the various fusion transcripts
could be demonstrated, while histologically the sarcoma
was revised to myxoid liposarcoma. Furthermore, a classic
translocation was identiﬁed in all revised round cell lipo-
sarcomas that were analyzed.
Molecular biological analysis reclassiﬁed 5/11 that had
been determined to be pleomorphic at revision. In ﬁve cases
an ampliﬁcation of region 12q13-15 was demonstrated.
Inclusion of molecular biological information as col-
lected for this study resulted in reclassiﬁcation in 4/18
(22%) cases in the time period 1977–1986. Molecular
biological analysis refuted the revised histological diag-
nosis in 10/38 (26%) of cases between 1987 and 1996 and
in 19/75 (25%) cases between 1997 and 2006.
DISCUSSION
This study indicates that expert revision is helpful in
ﬁrmly delineating the tumor classiﬁcation, especially when
supported by molecular biological analysis.
TABLE 2 Changes of revised histologic classiﬁcation after molecular biological analysis, which was performed in 131 patients, and the
additional 34 lipomas randomly retrieved from The Netherlands Cancer Institute ﬁles to complete the lipomatous tumor spectrum
Revision classiﬁcation Molecular biological analysis Deﬁnitive diagnosis Change diagnosis
Lipoma (34) Ampliﬁcation ? 1 WLS 1/34 (3%)
Ampliﬁcation – 33 Lipoma
WLS (63) Ampliﬁcation ? 47 WLS
Ampliﬁcation – 13 Lipoma 15/63 (23%)
Translocation – 1 WLS
Both ampliﬁcation and translocation – 2 Lipoma
DLS (14) Ampliﬁcation ? 9 DLS
Ampliﬁcation – 4 PLS 4/14 (29%)
Translocation – 1 DLS
MLS (32) Ampliﬁcation ? translocation – 11 WLS/DLS
Ampliﬁcation – 2 MLS
Translocation ? 18 MLS 12/32 (38%)
Translocation – 1 WLS/myxoﬁbrosarcoma
RLS (9) Translocation ? 9 RLS 0/9 (0%)
PLS (11) Ampliﬁcation ? 5 DLS 5/11 (45%)
Ampliﬁcation – 6 PLS
Sarcoma n.o.s. (2) Ampliﬁcation ? 1 DLS n.a.
Translocation – 1 WLS
165 165 37/ 163 (23%)
n.a = 2
N = 165
WLS, well-differentiated liposarcoma, DLS dedifferentiated liposarcoma, MLS myxoid liposarcoma, RLS round cell liposarcoma, PLS pleo-
morphic liposarcoma, N.O.S. not otherwise speciﬁed, Ampliﬁcation ampliﬁcation of region 12q13-15, Translocation detection of FUS–CHOP or
EWS–CHOP gene fusion
? present, – absent
690 R. S. A. de Vreeze et al.Due to their heterogeneity, the frequency of discordant
histopathological classiﬁcation is higher in liposarcoma
than in many other sarcomas. Diagnosis discrepancies in
soft tissue sarcoma are reported by others.
16–19 However,
these reports described sarcomas in general without
molecular biological analysis.
Considering the present treatment protocols, a therapy
change would have been indicated in 35/172 (20%) cases
based on histological revision alone and in 28/163 (17%)
cases based on molecular biological analysis. Most changes
at histologic revision were referred lipomas that were
revised to well-differentiated liposarcoma, for which a
more complete local resection is mandatory and follow-up
should be prolonged. For myxoid liposarcoma, concor-
dance was high with the exception of retroperitoneal
tumors with morphological features mimicking myxoid
liposarcoma. In pleomorphic liposarcoma, well-differenti-
ated components were often not recognized in otherwise
high-grade tumors.
The subgroup of well-differentiated liposarcoma needs
further illustration. This histologic classiﬁcation provided
by referring hospital showed a signiﬁcant lower 10-year
survival (58%) when compared with patients with that
same diagnosis after histological revision in our referral
center (80%; P\0.004). In histologically revised well-
differentiated liposarcomas, 10-year survival tended to be
better in nonampliﬁed lipomatous tumors (100%) than in
ampliﬁed liposarcomas (P = 0.066) (Fig. 1c). Moreover
no disease-speciﬁc events were observed in the three ret-
roperitoneal lesions that were histologically classiﬁed as
well-differentiated liposarcoma but in which no ampliﬁ-
cation of region 12q13-15 was found (Fig. 1d). One of the
explanations for these results may be that a (lipo)sarcom-
atous transformed component was missed by the referring
pathologist in 4/25 lipomatous tumor cases. Secondly,
survival differences between all revised well-differentiated
liposarcomas that underwent molecular biological analysis
were remarkable. The insights in the molecular pathogen-
esis of lipomatous tumors show a morphological overlap
between ordinary lipomas and well-differentiated liposar-
comas in 16/97 (16%) cases. The present study indicates
that their position in the spectrum can be determined by
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FIG. 1 a Survival curves of primary liposarcoma patients based on
revised histological classiﬁcation. b Ten-year survival of revised
extremity well-differentiated liposarcoma and survival of retroperi-
toneal well-differentiated liposarcoma. c Survival of all revised well-
differentiated liposarcomas that were molecular biologically
analyzed. The lower line indicates the ampliﬁed lipomatous tumors;
the upper line indicates the nonampliﬁed patients (P B 0.066). d Ten-
year survival of revised well-differentiated retroperitoneal liposar-
coma, ampliﬁed versus nonampliﬁed
Classiﬁcation and Therapy Decisions 691means of molecular biological analysis. It should be noted
that molecular analysis for liposarcoma in general may not
be necessary in any case, and results should interpreted
with caution and by experienced pathologists.
Classiﬁcation of pleomorphic liposarcoma in literature
is predominantly performed on the basis of histopatholo-
gical analysis only, occasionally in combination with
indistinct immunohistochemical markers.
20–25 However, it
appears that MDM2 and CDK4, are targeted most fre-
quently in well-differentiated and dedifferentiated
liposarcomas.
8,9,26–29 One may therefore assume that
pleomorphic liposarcoma expressing MDM2 or CDK4
ampliﬁcation represents dedifferentiated liposarcoma
without well-differentiated component. The histologic
classiﬁcation of pleomorphic liposarcoma is frequently
questionable (Table 2). The molecular biological MDM2
and CDK4 analysis indicates that the diagnosis was dis-
putable in 5/11 (45%) pleomorphic liposarcoma patients. It
is possible that the incidence of the histologic diagnosis
pleomorphic liposarcoma will continue to decrease due to
the introduction of additional molecular biological analysis
or immunohistochemical staining with MDM2 and CDK4
for all liposarcomas.
A few comments on our study are warranted. Firstly, in
this study we predominantly used either multiplex ligation-
dependent probe ampliﬁcation or RT-PCR for analysis.
These analyses were used in combination with histologic
information to deﬁne a classiﬁcation. In case of negative
translocation or ampliﬁcation analysis it must be noted
that, in order to positively establish a well-/dedifferentiated
liposarcoma character or myxoid/round cell liposarcoma,
sometimes a combination of methods can lead to an
undisputable diagnosis. Secondly, it should be realized that
survival of liposarcoma patients probably also depends on
tumor percentage dedifferentiation or percentage round cell
component. Liposarcoma survival curves including
molecular biologically deﬁned classiﬁcations could
improve accuracy. Finally, 10-year survival ranges from
around 20% for high-grade dedifferentiated retroperitoneal
liposarcoma up to 100% for low-grade well-differentiated
liposarcomas on the extremity. Treatment for the former
patients is complex and requires a multidisciplinary sar-
coma team.
30–34 Although in high-grade retroperitoneal
cases referral to a sarcoma center is common, referral is
sometimes omitted in more unclear cases. Due to a mor-
phological continuum of lipomas and liposarcomas, exact
recommendations to refer liposarcomas or to perform
molecular biological analysis, in apparent straightforward
cases, are difﬁcult to make.
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